Pharmamarketeer

EMA validates Vertex’s MAA for elexacaftor, tezacaftor & ivacaftor triple combination treatment in CF

Vertex Pharmaceuticals Limited, a global biotechnology company, announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for the VX─445 (elexacaftor), tezacaftor and ivacaftor triple combination regimen.

Medhc-fases-banner
Advertentie(s)